

# Development of a lead compound for anti-cancer drug using immunoactive attenuated Salmonella

CNCure Biotech Inc.



ONCOLOGY	Lead
Product Type	Biopharmaceuticals
Indication	Solid cancer
Target	Solid cancer patient
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>① Attenuated Salmonella typhimurium</li> <li>② Tumor targeting function by motility and chemotaxis</li> <li>③ Tumor necrosis and immune activation induced by bacteria</li> <li>④ Expressing immunoreactive anticancer proteins to activate immune response within the tumor microenvironment at a given time by induction</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>① Tumor-selective colonization and minimize non-specific normal tissue distribution</li> <li>② Attenuation with deletion of virulence genes or pathogenic genes (low toxicity)</li> <li>③ Easy drug removal using antibiotics</li> <li>④ Maximized drug delivery by non-invasive methods</li> <li>⑤ Induced long-term anticancer immune memory response</li> </ul>
Development Stage	Lead
Route of Administration	Intravenous injection